Tamoxifen: a most unlikely pioneering medicine

@article{Jordan2003TamoxifenAM,
  title={Tamoxifen: a most unlikely pioneering medicine},
  author={V Craig Jordan},
  journal={Nature Reviews Drug Discovery},
  year={2003},
  volume={2},
  pages={205-213}
}
  • V. Jordan
  • Published 1 March 2003
  • Medicine, Biology
  • Nature Reviews Drug Discovery
For more than 25 years, tamoxifen has been the gold standard for the endocrine treatment of all stages of oestrogen-receptor-positive breast cancer, and the World Health Organization lists tamoxifen as an essential drug for the treatment of breast cancer. It is estimated that more than 400,000 women are alive today as a result of tamoxifen therapy, and millions more have benefited from palliation and extended disease-free survival. Interestingly, tamoxifen also became the first cancer… 

Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer.

  • V. Jordan
  • Medicine
    Endocrine-related cancer
  • 2014
This success story is that success story, with a focus on the interdependent components of: excellence in drug discovery, investment in self-selecting young investigators, conversation with Nature, a conversation between the laboratory and the clinic, and the creation of the Oxford Overview Analysis.

Tamoxifen: catalyst for the change to targeted therapy.

  • V. Jordan
  • Medicine, Biology
    European journal of cancer
  • 2008

Adherence to long-term adjuvant hormonal therapy for breast cancer

  • C. GotayJ. Dunn
  • Medicine
    Expert review of pharmacoeconomics & outcomes research
  • 2011
The most recent literature reporting adherence rates for tamoxifen and AIs, as well as correlates of adherence are reviewed, including the side-effect profile, and approaches to intervention to enhance adherence are discussed.

The Consequences of Exhaustive Antiestrogen Therapy in Breast Cancer: Estrogen-Induced Tumor Cell Death

This minireview will describe the current strategies for the treatment and prevention of breast cancer and present emerging new concepts about the consequences of exhaustive antiestrogen treatment on therapeutic resistance.

Optimizing the antihormonal treatment and prevention of breast cancer

The therapeutic options for anti-hormonal therapy, the role of anti-Hormonal agents in advanced breast cancer, and adjuvant therapy and the current status of chemoprevention with selective ER modulators are summarized.

SERMs: meeting the promise of multifunctional medicines.

  • V. Jordan
  • Medicine, Biology
    Journal of the National Cancer Institute
  • 2007
The successful development and clinical evaluation of the selective estrogen receptor modulators in the Study of Tamoxifen and Raloxifene trial provides an occasion to reflect on the milestone that

Targeting antihormone resistance in breast cancer: a simple solution.

  • V. Jordan
  • Biology, Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2003
In this issue of Annals of Oncology, deGraffenried et al. illustrate a simple strategy for restoring antiestrogen responsiveness in cells engineered to be intrinsically resistant, and find that tamoxifen sensitivity is restored.

Precision Medicine in Hormone Receptor-Positive Breast Cancer

The opportunities and challenges in integrating precision medicine through next-generation genomic sequencing into the management of breast cancer are discussed.

Oestrogens, Oestrogen Receptors and Breast Cancer

Progress in endocrine approaches to the treatment and prevention of breast cancer.

...

References

SHOWING 1-10 OF 132 REFERENCES

The development of tamoxifen for breast cancer therapy: A tribute to the late Arthur L. Walpole

  • V. Jordan
  • Medicine, Biology
    Breast Cancer Research and Treatment
  • 2005
SummaryTamoxifen, a nonsteroidal antiestrogen, is now the endocrine treatment most widely used in breast cancer, both in the adjuvant and advanced disease settings. Here we will trace the development

ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERS

A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer.

Results of this pilot trial of tamoxifen, an anti-oestrogen, compared to placebo given to 200 women at a high risk of developing breast cancer show that acute toxicity is low and that accrual and compliance are satisfactory, and biochemical monitoring of lipids and clotting factors indicate that tamoxify may reduce the risk of cardiovascular deaths.

Anti-oestrogen Therapy for Breast Cancer: A Trial of Tamoxifen at Two Dose Levels

  • H. Ward
  • Medicine
    British medical journal
  • 1973
Tamoxifen (ICI 46474) was given by mouth to patients with advanced, recurrent, or metastatic breast carcinoma. At a dosage of 10 mg twice daily 60% of patients showed arrest or reversal of tumour

Tamoxifen and contralateral breast cancer.

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

Tamoxifen decreases the incidence of invasive and noninvasive breast cancer and its use as a breast cancer preventive agent is appropriate in many women at increased risk for the disease.

Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer.

Since there was no statistically significant difference in efficacy and since tamoxifen was less toxic, tamoxIFen appears to be the preferred agent.
...